Meta-analysis: The efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy

Renal Failure

Volumn 37, Issue 4, 2015, Pages 548-561

  Ren, Feifeng ^a   Tang, Lin ^a   Cai, Yin ^a   Yuan, Xin ^a   Huang, Wenhan ^a   Luo, Lei ^a   Zhou, Jun ^a   Zheng, Yaning ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

ACEI; ARB; Combined treatment; Diabetic nephropathy; Meta analysis

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPOTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; REVIEW; TREATMENT INDICATION; URINARY EXCRETION; DIABETIC NEPHROPATHIES; DRUG COMBINATION; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 84930329477     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2015.1012995     Document Type: Review

References (50)

1. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005;94:S14-S18.
2. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic Nephropathy. Diabetes Care. 2003; 26(Suppl 1):S94-S98.
3. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care. 2004;27:1330-1334.
4. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in Type 2 diabetes with overt nephropathy: A multicentre, randomized, placebo-controlled study. Diabetologia. 2011;54:2978-2986.
5. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
6. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-Analysis. Diabet Med. 2007;24:486-493.
7. Linda FF, Nicholas E, Jane HZ, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. New Engl J Med. 2013;369:1892-1903.
8. Mann JF, Anderson C, Gao P, et al. Dual inhibition of the reninangiotensin system in high-risk diabetes and risk for stroke and other outcomes: Results of the ONTARGET Trial. J Hypertens. 2013;31:414-421.
9. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Accessed October 1, 2011.
10. Agarwal A. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int. 2001;59:2282-2289.
11. Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ace inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003;63:1094-1103.
12. Mann JF, Schmieder RE, ONTARGET Investigators, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the Ontarget Study): A multicentre, randomized, double-blind, controlled trial. Lancet. 2008;372:547-553.
13. Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM. Combination is better than monotherapy with ace inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst. 2003;4:43-47.
14. Vidt DG. Telmisartan, ramipril, or both in patients at high risk for vascular events. Curr Hypertens Rep. 2008;10:343-344.
15. Fujisawa T, Ikegami H, Ono M, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens. 2005; 18:13-17.
16. Hebert LA, Falkenhain M, Nohman N, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist in diabetic nephropathy. Am J Nephrol. 1999;19:1-6.
17. Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med. 2006;119:S40-S47.
18. Hirohiko ABE, Shinya M, Hiroshige O, et al. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy. Hypertens Res. 2007;30:929-935.
19. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW. Long-Term dual blockade with candesartan and Lisinopril in hypertensive patients with diabetes. Diabetes Care. 2005;28:273-277.
20. Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type II diabetes. Int J Clin Pract. 2004;58: 432-435.
21. Fernandez Juarez G, Luno J, Barrio V, et al. Effect of dual blockade of the renin-Angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial. Am J Kidney Dis. 2013; 61:211-218.
22. Igarashi M, Hirata A, Kadomoto Y, Tominaga M. Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. Endocr J. 2006;53: 493-501.
23. Jacobsen P, Anderson S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14:992-999.
24. Jacobsen P, Anderson S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-Angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63:1874-1880.
25. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-Angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant. 2002;17: 1019-1024.
26. Kim MJ, Song JH, Suh JH, Lee SW, Kim GA. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin receptor antagonist: Differential short-Term response between IgA nephropathy and diabetic nephropathy. Yonsei Med J. 2003;44:463-472.
27. Krairittichai U, Chaisuvannarat V. Effects of dual blockade of renin-Angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. J Med Assoc Thai. 2009;92:611-617.
28. Kuriyama S, Tomonari H, Tokudome G, et al. Anti-proteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res. 2002;25: 849-855.
29. Matos JPS, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin Nephrol. 2005;64:180-189.
30. Mogensen CE, Neldam S, for the CALM study group, et al. Randomized controlled trial of the dual blockade of renin-Angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and Lisinopril microalbuminuria (CALM) study. BMJ. 2000;321: 1440-1444.
31. Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res. 2007;30:325-334.
32. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care. 2003;26: 2268-2274.
33. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-Angiotensin system in diabetic nephropathy: A randomized double-blind crossover study. Diabetes Care. 2002; 25:95-100.
34. Sengul AM, Altuntas Y, Kurklu A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pr. 2006; 71:210-219.
35. Song JH, Cha SH, Lee HJ, et al. Effect of low-dose dual blockade of renin-Angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant. 2006;21:683-689.
36. Tütüncü NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: A prospective study. Acta Diabetol. 2001;38:157-161.
37. Titan SM, Vieira Jr. JM, Dominguez WV, Barros RT, Zatz R. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: A double-blind randomized clinical trial. Clin Nephrol. 2011;76:273-283.
38. Bei J, Xianhua L, Xiangdong Y, Jian S, Ling G, Zhao H. Renoprotective effects of dual blockade of renin-Angiotensin system in diabetic nephropathy. J Shandong Univ (Health Sci). 2006;59: 896-899.
39. Xinxia H, Weihong H, Yan X, Hongyan W, Le W. Clinical study of the protective effect of ACEI and ARB on patients with diabetic nephropathy. Chin J Prev Control Chronic Dis. 2007;15:34-35.
40. Yuan-Hang H, Haitao W, Qizhi Z, Hong Z, Wen S, Yin W. Combination therapy with losartan and fosinopril for early diabetic nephropathy. J First Mil Med Univ. 2003;23:963-965.
41. Dongmei J, Wei L, Shangwen W, Zhenzhong X. The efficiency of combined treatment with benazepril and valsartan on thirty patients with diabetic kidney disease. Shandong Med J. 2007;47:69-70.
42. Yuan-Zhou L, Guiping L, Aiwen C, Ruyi Z. The efficacy of combined treatment with benazepril and losartan on early type 2 diabetic nephropathy and hypertension. Guangdong Med J. 2011; 32:2991-2993.
43. Huizhen L, Wen L, Jinrong L, Qiujun Z, Xiuyun L, Gaiying H. The efficiency of dual blockade of the renin-Angiotensin system on patients with diabetic nephropathy. Chin J Gerontol. 2011;31: 1964-1966.
44. Wei L. The efficiency of combined treatment with perindopril and valsartan on diabetic nephropathy. Shandong Med J. 2010;50: 107-108.
45. Longqing W, Lixia L, Junyan M. Clinical application of combination ACEI with losartan in treating diabetic nephropathy. J Beihua Univ (Nat Sci). 2000;1:506-508.
46. Liang X, Shuhong Z. The efficiency of combined treatment with imidapril and valsartan on thirty-Two patients with early diabetic nephropathy. China J Mod Med. 2007;17:1130-1131.
47. Ling Z, Jiansheng N. The efficacy and safety of combined treatment with enalapril and losartan on early type 2 diabetic nephropathy and hypertension. Chin J Gerontol. 2013;33:2038-2040.
48. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-392.
49. Mckelvie RS, Yusuf S, Pericak D, Gomis R, Andersen S, Arner P. Comparison of candesartan, enalapril, and their combination in congestive heart failure. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056-1064.
50. Imig JD. ACE inhibition and bradykinin-mediated renal vascular responses: EDHF involvement. Hypertension. 2004;43: 533-535.